Log in

goodpods headphones icon

To access all our features

Open the Goodpods app
Close icon
Dementia Researcher - A Closer Look At Lecanemab Donanemab And Amyloid

A Closer Look At Lecanemab Donanemab And Amyloid

11/13/23 • 54 min

2 Listeners

Dementia Researcher
In this podcast Dr Anna Volkmer, convenes a panel of world-renowned experts from University College London. They discuss the discovery of amyloid and its role in Alzheimer’s Disease and take an in-depth look into the latest developments surrounding Lecanemab and Donanemab, monoclonal antibodies (mAbs) as a treatment and Gene Silencing. This week’s guests are Professor Sir John Hardy, Geneticist and trailblazer in neurodegenerative disease research, Professor Nick Fox, Neurologist, and eminent figure in the fields of neuroimaging and clinical neuroscience, and Dr Cath Mummery, Neurologist and leading light in cognitive disorders and clinical trials. -- Listeners can expect: 1. 🧠 - Discussion on new dementia drugs Lecanemab and Donanemab. 2. 🔬 - Insights on the science behind these treatments, the story behind the discovery of amyloid and familial Alzheimer’s - Carol Jennings Story. 3. ❌🤔 - Clarification of misconceptions about dementia therapies. 4. 🩺💊 - Information on the impact of these drugs on patients and clinical practice. 5. 🌟🔜 - A look at the future of dementia research, including gene-silencing therapies. -- NIA statement on report of lecanemab reducing cognitive decline in Alzheimer’s clinical trial: https://www.nia.nih.gov/news/nia-statement-report-lecanemab-reducing-cognitive-decline-alzheimers-clinical-trial NIA statement on donanemab results: More Alzheimer’s research progress: https://www.nia.nih.gov/news/nia-statement-donanemab-results-more-alzheimers-research-progress Alzheimer's Society Information on Donanemab: https://www.alzheimers.org.uk/blog/what-is-donanemab-alzheimers-drug Alzheimer's Society Information on Lebanemab: https://www.alzheimers.org.uk/blog/lecanemab-new-drug-early-stage-alzheimers-disease Alzheimer's Association Info on Research & Risks https://bit.ly/3QxH3Ei -- Full biographies on all our guests and a transcript can be found on our website http://www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you’ll find a video version of this podcast with full captions on our YouTube Channel. https://youtu.be/Kl8rzDSIwxM -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer’s Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.
plus icon
bookmark
In this podcast Dr Anna Volkmer, convenes a panel of world-renowned experts from University College London. They discuss the discovery of amyloid and its role in Alzheimer’s Disease and take an in-depth look into the latest developments surrounding Lecanemab and Donanemab, monoclonal antibodies (mAbs) as a treatment and Gene Silencing. This week’s guests are Professor Sir John Hardy, Geneticist and trailblazer in neurodegenerative disease research, Professor Nick Fox, Neurologist, and eminent figure in the fields of neuroimaging and clinical neuroscience, and Dr Cath Mummery, Neurologist and leading light in cognitive disorders and clinical trials. -- Listeners can expect: 1. 🧠 - Discussion on new dementia drugs Lecanemab and Donanemab. 2. 🔬 - Insights on the science behind these treatments, the story behind the discovery of amyloid and familial Alzheimer’s - Carol Jennings Story. 3. ❌🤔 - Clarification of misconceptions about dementia therapies. 4. 🩺💊 - Information on the impact of these drugs on patients and clinical practice. 5. 🌟🔜 - A look at the future of dementia research, including gene-silencing therapies. -- NIA statement on report of lecanemab reducing cognitive decline in Alzheimer’s clinical trial: https://www.nia.nih.gov/news/nia-statement-report-lecanemab-reducing-cognitive-decline-alzheimers-clinical-trial NIA statement on donanemab results: More Alzheimer’s research progress: https://www.nia.nih.gov/news/nia-statement-donanemab-results-more-alzheimers-research-progress Alzheimer's Society Information on Donanemab: https://www.alzheimers.org.uk/blog/what-is-donanemab-alzheimers-drug Alzheimer's Society Information on Lebanemab: https://www.alzheimers.org.uk/blog/lecanemab-new-drug-early-stage-alzheimers-disease Alzheimer's Association Info on Research & Risks https://bit.ly/3QxH3Ei -- Full biographies on all our guests and a transcript can be found on our website http://www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you’ll find a video version of this podcast with full captions on our YouTube Channel. https://youtu.be/Kl8rzDSIwxM -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer’s Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.

Previous Episode

undefined - Alzheimer Europe Conference Roundup 2023

Alzheimer Europe Conference Roundup 2023

2 Recommendations

Last week Adam Smith attended the 33rd Alzheimer Europe Conference in Helsinki, Finland. In this podcast Adam and his guests bring you highlights from event, sharing news and their best bits from the hundreds of posters and talks delivered. -- This week’s guests are: Dr Victoria Shepherd, Senior Research Fello and Nurse from Cardiff University. Victoria has a special interest in research involving under-served populations with a particular focus on people with cognitive impairment. She leads a programme of methodological research exploring the ethical, legal and practical issues around research involving adults who lack capacity consent. Dr Monica Leverton, Postdoctoral Researcher at King’s College London. Monica is based within the NIHR policy institute in health and social care workforce. Her areas of interest include care for people living with dementia and the social care workforce who support them. She currently leads a project developing the role of dementia champions in homecare. Dr Danielle Jones, Associate Professor in Dementia Studies at University of Bradford. Danielle is a medical sociologist with expertise in Conversation Analysis. She has applied this method to medical communication to investigate how dementia is assessed within memory clinics in the UK. Her current project explores how dementia risk is communicated in medical interaction within both primary and secondary care. Caroline Bartle, Dementia Project Specialist at Ryman Health Care in New Zealand. Caroline has 30 years in dementia care – carer to social worker to CEO – leading workforce development in dementia care. Founder of 3 Spirit Training Consultancy who has trained over 100,000 carers and developed over 500 different health and social care programmes. -- This year’s conference was held under the motto “New opportunities in dementia care, policy and research”. As in previous years, this conference is one of the few in the diary that has a ‘family feel; providing great networking opportunities and bringing together people living with dementia, carers, volunteers and staff of European Alzheimer associations, policy makers, health and social care professionals, researchers and academics. This year had a record turn-out of 1,000 in-person attendees, enjoying a programme covering a broad range of topics, from fundamental science to care, diagnosis, policies, interventions, treatments and more (and for the first-time sessions led and decided by their European Working Group of People with Dementia (EWGPWD) and European Dementia Carers Working Group (EDCWG)). -- Links discussed in the show: Conference Website - https://bit.ly/3seI5g4 Conference hashtag - https://bit.ly/45R0RYX EU-Fingers - https://eufingers.com/ INTERDEM - https://interdem.org/ -- You can find out more about our panellists, and their work on our website. There you will also find a full transcript: https://www.dementiaresearcher.nihr.ac.uk -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of Dementia Researcher or its supporters.

Next Episode

undefined - Improving Dementia Care Journeys

Improving Dementia Care Journeys

1 Recommendations

This episode of the Dementia Researcher Podcast is hosted by Dr. Annalise Rahman-Filipiak and features Diane Ty and Rajiv Ahuja, authors of a pivotal report from the Milken Institute - Guiding the Care Journey. In this show we discuss the report, its importance an findings - addressing critical challenges and presenting innovative solutions for dementia care in the United States, with a particular focus on the role of the care navigators. While the report primarily addresses the U.S. context, its recommendations are deemed relevant globally, and the discussion aims to shed light on findings related to improving care for people living with dementia and their families, wherever you are. -- Download the report: https://bit.ly/3uEgvtq Visit the Milken website: https://milkeninstitute.org/ -- About the guests: Diane Ty is the Senior Director of the Milken Institute Future of Aging overseeing its work at the intersection of healthy longevity and financial security. She leads its Alliance to Improve Dementia Care and other multisector programmatic efforts that promote policy, practice, and systems change in a life course approach to aging. Rajiv Ahuja is the Associate Director of the Milken Institute Future Ageing. His work focuses on aging policies and programs that support healthy longevity. Rajiv spearheads efforts to incentivize policy, business, and technology-based approaches that promote brain health, combat stigma, reduce costs, and bridge health and economic disparities. Dr Annalise Rahman-Filipiak is an Assistant Professor, Clinical Neuropsychologist at University of Michigan. Annalise broadly studies racial-ethnic disparities in dementia diagnosis and treatment, as well as non-pharmacologic treatments for Alzheimer’s disease and related dementias. Her recent work has focused on disclosure of imaging and fluid-based biomarkers to diverse audiences, including cognitively healthy older adults and those with impairment -- Full biographies on all our guests and a transcript can be found on our website https://www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than watch, you’ll find a video version of this podcast with full captions on YouTube and our website: https://youtu.be/rvjpPsdIyQc -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer’s Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support. -- Follow us on Social Media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ @MilkenInstitute #dementiacare #dementiaresearch #CareNavigator #dementia #alzheimerdisease #DemetiaCare,

Episode Comments

Generate a badge

Get a badge for your website that links back to this episode

Select type & size
Open dropdown icon
share badge image

<a href="https://goodpods.com/podcasts/dementia-researcher-152321/a-closer-look-at-lecanemab-donanemab-and-amyloid-36490721"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to a closer look at lecanemab donanemab and amyloid on goodpods" style="width: 225px" /> </a>

Copy